BET
44 programs · 44 companies
Programs
44
Companies
44
Active Trials
29
Targeting BET
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | MCLEwing Sarcoma | |
| RHH-1969 | Roche | Approved | MSPBC | |
| NVS-5439 | Novartis | Preclinical | SCD | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | Parkinson's | |
| Adagracapivasertib | BeiGene | NDA/BLA | GAParkinson's | |
| 207-5197 | Samsung Biologics | Approved | SchizophreniaET | |
| ILM-5680 | Illumina | Phase 2 | MSGIST | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | PAHHuntington's | |
| Voxamavacamten | Corcept | Approved | PNHCeliac | |
| RXR-1394 | Recursion | Phase 3 | MesoBreast Ca | |
| Semalucimab | Zealand Pharma | Phase 3 | DMD | |
| Zenozasiran | Cipla | Preclinical | PsAFSGS | |
| Doxafutibatinib | Mesoblast | Phase 1 | ACCNASH | |
| NIA-IIT-441 | NIAID | Phase 2 | EoE | |
| Ivomavacamten | Cerevel (AbbVie) | Phase 1/2 | AsthmaPTSD | |
| Tirasacituzumab | Forma (Novo) | NDA/BLA | OCD | |
| Doxalucimab | Maze Ther | Phase 1/2 | OCD | |
| CRB-6490 | Corbus Pharma | Approved | SMAMyelofibrosis | |
| Voxacapivasertib | Keros Ther | Phase 1/2 | MS | |
| Niraglumide | Eledon Pharma | Phase 1/2 | DLBCL | |
| AGO-8938 | Agora Inc | Phase 2 | MGHeart Failure | |
| Miritinib | I-Mab | Phase 2/3 | TTR AmyloidosisBCC | |
| MYO-4326 | Myokardia (BMS) | Phase 2/3 | EoE | |
| Rimanesiran | Loxo (Lilly) | Phase 3 | DMDMDD | |
| Tirazasiran | Clementia (Ipsen) | Phase 1/2 | WilmsMCL | |
| Zanufotisoran | Synthorx (Sanofi) | Approved | CKDADPKD | |
| Pemifutibatinib | Kelun-Biotech | Phase 3 | MDSHemophilia A | |
| LMN-8636 | Liminal Bio | Phase 3 | LGS | |
| ADA-3632 | Adamas (Supernus) | NDA/BLA | FSGSPompe | |
| SEN-1840 | Sensei Bio | Phase 2 | Rett | |
| Ribozanubrutinib | Monte Rosa | Phase 1 | RBCrohn's | |
| DAI-6285 | Daiichi Sankyo EU | Phase 1/2 | Pompe | |
| Mirifotisoran | Nippon Shinyaku | Approved | PSPCML | |
| Gozefutibatinib | HK Inno.N | Phase 1/2 | T2DMM | |
| DPH-273 | Dechra Pharma | NDA/BLA | Wilms | |
| Sovasacituzumab | Vaccibody (Nykode) | Phase 2/3 | CeliacPBC | |
| CNT-5081 | Centogene | Phase 3 | LGSPSP | |
| Lisovorutinib | Helixmith | Phase 2/3 | AngelmanCKD | |
| Zoriratamab | Alkem Labs | Preclinical | TTR Amyloidosis | |
| LAB-3189 | Laboratorio Chile | Phase 3 | CTCL | |
| NAT-IIT-714 | Natl Cancer Ctr Singapore | Phase 3 | Psoriasis | |
| ACG-4705 | Aceragen | NDA/BLA | Bladder CaEndometrial Ca | |
| Gozesotorasib | Veracyte | Phase 1/2 | HCC | |
| Surarasimod | Castle Biosciences | Phase 2 | SCDCRC |